Longeveron (NASDAQ: LGVN)

LGVN · Nasdaq · United States

Share price · LGVN

$1.92-5.95 (-75.61%) 3M

close as of 2026-11-18 · 24h delayed · vol 82K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LGVN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+41.3%
  2. 14 Oct 2026-19.5%
  3. 17 Sep 2026-59.4%
  4. 11 Sep 2026+10.4%

    Nothing announced by LGVN that day or the session before.

  5. 25 Aug 2026-18.8%
  6. 17 Aug 2026+10.8%

    Nothing announced by LGVN that day or the session before.

  7. 30 Jul 2026+13.4%
  8. 24 Jun 2026-7.5%
  9. 13 Mar 2026+20.4%
  10. 10 Mar 2026+68.1%

Share of unusual movement by asset

For each asset, the share of LGVN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Laromestrocel (Lomecel-B)
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—12%
Other company news (earnings, financing, releases naming no asset)—38%
Sessions with no dated event—50%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Laromestrocel(Lomecel-B)
Phase 2
Mesenchymal stem cell therapyCell therapy
Alzheimer's DiseaseHypoplastic Left Heart Syndrome

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 September 2026Topline resultLaromestrocelELPIS II Phase 2b trial missed its primary endpoint
Longeveron Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.1M$4.0M$7.3M$6.1M-$2.7M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$3.2M$10M$6.1M-$5.7M operating cash flowreport ↗
2026-Q1—$2.3M$16M$4.7M-$4.4M operating cash flowreport ↗
2025-Q3—$3.9M$9.2M$7.2M-$5.0M operating cash flowreport ↗
2025-Q2—$3.0M$10M$5.0M-$3.6M operating cash flowreport ↗
2025-Q1—$2.5M$14M+ $0 short-term inv.$5.0M-$4.7M operating cash flowreport ↗
2024-Q3—$2.2M$23M+ $0 short-term inv.$4.4M-$2.8M operating cash flowreport ↗
2024-Q2—$1.7M$12M$3.4M-$4.6M operating cash flowreport ↗
2024-Q1$0.6M$2.2M$1.9M+ $0.3M short-term inv.$4.1M-$3.1M operating cash flowreport ↗
2023-Q3$0.1M$1.8M$2.0M+ $2.0M short-term inv.$5.1M-$4.6M operating cash flowreport ↗
2023-Q2$0.2M$2.3M$2.8M+ $5.9M short-term inv.$5.6M-$4.6M operating cash flowreport ↗
2023-Q1$0.3M$2.8M$5.0M+ $0.4M short-term inv.$4.7M-$5.8M operating cash flowreport ↗
2022-Q3$0.3M$3.0M$14M+ $8.7M short-term inv.$5.2M-$4.2M operating cash flowreport ↗
2022-Q2$0.5M$1.7M$20M+ $7.1M short-term inv.$5.6M-$3.3M operating cash flowreport ↗
2022-Q1$0.4M$1.4M$22M+ $8.5M short-term inv.$3.5M-$4.2M operating cash flowreport ↗
2021-Q3$0.2M$2.0M$9.7M+ $9.2M short-term inv.$4.9M-$2.4M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$12M$4.7M$5.7M-$19M operating cash flowreport ↗

For fiscal year 2025, Longeveron did not disclose revenue. R&D spend was $12.04M, up 47.9% YoY, while cash and equivalents stood at $4.66M. The company reported a net loss of $22.7M and a quarterly net burn of $22.7M.

Longeveron is advancing laromestrocel across HLHS, Alzheimer’s disease, pediatric DCM, and aging-related frailty. The ELPIS II Phase 2b HLHS trial reached full enrollment on June 24, 2025, with top-line results anticipated in Q3 2026 and an FDA Type C meeting scheduled for late March 2026. In mild Alzheimer’s disease, a positive Type B meeting in March 2025 supported a proposed pivotal Phase 2/3 registrational design. An IND for pediatric DCM became effective in July 2025, with a single pivotal Phase 2 trial planned to begin preparation in 2026, and the company discontinued its Japan frailty trial in April 2024.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$8.1M$19M+ $0 short-term inv.$4.0M-$14M operating cash flowreport ↗
2023-FY$0.7M$9.1M$5.0M+ $0.4M short-term inv.$5.3M-$19M operating cash flowreport ↗
2022-FY$1.2M$9.4M$11M+ $9.2M short-term inv.$4.7M-$14M operating cash flowreport ↗
2021-FY$1.3M$7.1M$26M+ $9.5M short-term inv.$4.3M-$9.6M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-01Blass Devin · CTO & SVP of CMCTax withholding2,520$2.59$7KForm 4
2026-10-01Lehr Paul T · General Counsel, SecretaryTax withholding2,253$2.59$6KForm 4
2026-10-01Agafonova Nataliya · Chief Medical OfficerTax withholding2,913$2.59$8KForm 4
2026-10-01Willard Stephen H · Chief Executive OfficerTax withholding1,987$2.59$5KForm 4
2026-10-01Jhaveri Nirav S. · Chief Financial OfficerTax withholding742$2.59$2KForm 4
2026-08-19Hare Joshua · director, Chief Scientific Officer, 10% ownerAward / grant286,000——Form 4
2026-08-19Agafonova Nataliya · Chief Medical OfficerAward / grant286,000——Form 4
2026-08-19Ascheim Deborah · directorAward / grant36,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 31 reporting institutions held 2.3M shares ($2.2M, 7.3% of shares outstanding).

#InstitutionSharesValue
1VANGUARD CAPITAL MANAGEMENT LLC542,032$564K
2MILLENNIUM MANAGEMENT LLC446,725$465K
3BlackRock, Inc.224,198$233K
4GEODE CAPITAL MANAGEMENT, LLC203,618$212K
5ADAR1 Capital Management, LLC200,000$208K
6JANE STREET GROUP, LLC185,656$193K
7Beacon Pointe Advisors, LLC100,000$104K
8STATE STREET CORP45,380$47K
9VANGUARD FIDUCIARY TRUST CO38,715$40K
10Capital Investment Advisory Services, LLC26,525$28K
11COMMONWEALTH EQUITY SERVICES, LLC25,155$26K
12Hamilton Point Investment Advisors, LLC22,446$23K
13MONETA GROUP INVESTMENT ADVISORS LLC21,300$22K
14NORTHERN TRUST CORP19,779$21K
15UBS Group AG14,862$15K